A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)

Authors

Russell Kent Pachynski, Washington University School of Medicine, St. Louis, MO
Gurkamal S. Chatta, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Rohit K. Jain, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, FL
Helen H. Moon, Kaiser Permanente - Riverside Medical Center, Riverside, CA
Randy F. Sweis, The University of Chicago
Scott Delacroix, LSU Health Sciences Center - New OrleansFollow
T. Fang, PBS, Cytel Inc., Cambridge, MA
Steven P. Fling, Fred Hutchinson Cancer Research Center, Seattle, WA
Andreanne Lacroix, Fred Hutchinson Cancer Research Center, Seattle, WA
Judith Kaiser, Fred Hutchinson Cancer Research Center, Seattle, WA
Elad Sharon, National Cancer Institute, Bethesda, MD
Evan Y. Yu, Fred Hutchinson Cancer Research Center, Seattle, WA

Document Type

Conference Proceeding

Publication Date

10-20-2023

Publication Title

Annals of Oncology

Abstract

ESMO Congress 2023, October 20 - 24, 2023, Madrid, Spain

First Page

S1204

Last Page

S1205

Volume

34

Issue

Supplement 2

Comments

Abstract #2367P

Recommended Citation

Pachynski, Russell Kent; Chatta, Gurkamal S.; Jain, Rohit K.; Moon, Helen H.; Sweis, Randy F.; Delacroix, Scott; Fang, T.; Fling, Steven P.; Lacroix, Andreanne; Kaiser, Judith; Sharon, Elad; and Yu, Evan Y., "A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)" (2023). School of Medicine Faculty Publications. 2384.
https://digitalscholar.lsuhsc.edu/som_facpubs/2384
10.1016/j.annonc.2023.09.1016